X-Linked Retinitis PigmentosaXOLARISNCT04926129
Natural History of the Progression of X-Linked Retinitis Pigmentosa
An observational study of X-Linked Retinitis Pigmentosa, run by NightstaRx Ltd, a Biogen Company at 22 sites in 7 countries.
Trial summary
The objective of the study is to gain a better understanding of disease progression over time in participants with X-linked retinitis pigmentosa (XLRP). Read more about this study
- Who is it for?
- Ages 7 years and older
- Conditions the study is for
- X-Linked Retinitis Pigmentosa
- What is being tested?
- Other: Assessments
- How many people
- 201 participants
- Where
- 22 sitesin 7 countries
- Study dates
- 13 Sep 2017to 16 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: 201 participants with X-linked Retinitis Pigmentosa (XLRP).
Who may be able to join
- Have documentation of a pathogenic mutation in the retinitis pigmentosa GTPase regulator (RPGR) gene.
- Are willing and able to undergo ophthalmic examinations, as required by protocol, for up to 24 months
- Have an ETDRS BCVA in at least 1 eye of ≥34 letters (Equivalent to Snellen ≥ 6/60 or 20/200; decimal 0.1; LogMAR 1.0).
- Mean retinal sensitivity in the eligible eye as assessed by microperimetry:
- Males with a mean retinal sensitivity of 68 loci ranging from ≥0.1 decibels (dB) and ≤20 dB.
- Females with a mean retinal sensitivity of 68 loci ranging from ≥0.1 dB and ≤25 dB.
- If female, have symptomatic disease with impairment of visual function.
Who cannot join
- Have a history of amblyopia in the eligible eye.
- Have any other significant ocular or non-ocular disease/disorder which, in the opinion of the investigator, may put the participant at risk because of participation in the study, may influence the results of the study, may influence the participant's ability to perform study diagnostic tests, or impact the participant's ability to participate in the study. This includes clinically significant cataracts.
- Have participated in another research study involving an investigational medicinal product in the past 12 weeks or received a gene/cell-based therapy at any time previously (including but not limited to Intelligent Implant System implantation, ciliary neurotrophic factor therapy, nerve growth factor therapy).
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Trial locations and contacts
22 sites in 7 countries.
22 sites in 7 countries
United States10 sites
Research Site
Dallas, Texas, 75231
Research Site
Houston, Texas, 77030
Research Site
Los Angeles, California, 90095
Research Site
Madison, Wisconsin, 53705
Research Site
Miami, Florida, 33136
Research Site
New York, New York, 10032
Research Site
Phoenix, Arizona, 85020
Research Site
Portland, Oregon, 97239
Research Site
Salt Lake City, Utah, 84132
Research Site
San Francisco, California, 94143
United Kingdom4 sites
Research Site
Leeds
Research Site
Manchester
Research Site
Oxford
Research Site
Southampton
Canada2 sites
Research Site
Montreal, Quebec, H4A 3J1
Research Site
Vancouver, V5Z3N9
About this study
The objective of the study is to gain a better understanding of disease progression over time in participants with X-linked retinitis pigmentosa (XLRP).
Read the detailed description
This study was previously posted by NightstaRx Ltd. In October, 2020, sponsorship of the trial was transferred to Biogen.
- Conditions
- X-Linked Retinitis Pigmentosa
- Being tested
- Other: Assessments
- Keywords
- RP GTPase regulator (RPGR), Degenerative retinal disease, XLRP, Natural history, Rare disease
- Medical subject headings
- Rare Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Other: AssessmentsOther
Also called BIIB112
Administered as specified in the treatment arm.
| Study group | Role | What they receive |
|---|---|---|
| Subgroup 1 | Participant's eye with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) ≥74 letters (Equivalent to: Snellen 6/9 or 20/32; decimal 0.63; Logarithm of the minimum angle of resolution [LogMAR] 0.2) will be enrolled. Receives: Other: Other: Assessments | |
| Subgroup 2 | Participant's eye with ETDRS BCVA 34-73 letters, inclusive (Equivalent to: Snellen 6/12 - 6/60 or 20/40 - 20/200; decimal 0.5 - 0.1; LogMAR 0.3-1.0) will be enrolled. Receives: Other: Other: Assessments |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA)
BCVA will be assessed for both eyes using the ETDRS visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant.
Measured: Up to Month 24
Change from Baseline in Retinal Sensitivity Assessed with Microperimetry
Macular analyser integrity assessment (MAIA) microperimetry will be conducted for both eyes to assess changes in retinal sensitivity within the macula.
Measured: Up to Month 24
Secondary outcomes (17)
Change from Baseline in Contrast Sensitivity
Change from baseline in contrast sensitivity in the study eye is measured using a Pelli Robson contrast sensitivity chart at 1 meter. The contrast sensitivity chart contains letters that are darkest at the top and then get progressively lighter. Scores range from 0 to 48 and are based on the number of letters read correctly. A negative change from baseline indicates a worsening in contrast sensitivity and a positive change from baseline indicates an improvement.
Measured: Up to Month 24
Change from Baseline in Low Luminance Visual Acuity (LLVA)
LLVA is measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. LLVA is to be reported as number of letters read correctly by the participant.
Measured: Up to Month 24
Change from Baseline in 25-item Visual Function Questionnaire (VFQ-25) Score
VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.
Measured: Up to Month 24
Change from Baseline in Retinitis Pigmentosa (RP)-Specific Patient-Reported Outcome (PRO) Questionnaire
Measured: Up to Month 24
Change from Baseline in EuroQol-5 Dimension 5-level (EQ-5D-5L)
The widely validated EQ-5D includes 2 components, the EQ-5D descriptive system and the EQ VAS. The EQ-5D descriptive system provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the subject is instructed to indicate whether he or she has "no problems" (level 1), "slight problems" (level 2), "moderate problems" (level 3), "severe problems (level 4), or "extreme problems/inability" (level 5) on that day. For the EQ VAS, the participant is instructed to mark an "x" on a vertical scale at the point that best describes his or her own health on that day, where 0 represents the "worst health" he or she can imagine and 100 the "best health" he or she can imagine.
Measured: Up to Month 24
Change from Baseline in Health Utilities Index Mark 3 (HUI3)
The HUI3 is a generic 8-item survey, which provides descriptive evidence on multiple dimensions of health status, a score for each dimension of health, and a health-related quality of life score for overall health. Health dimensions include vision, hearing, speech, ambulation/mobility, pain, dexterity, emotion and cognition. Each dimension has five or six response options. Scores on individual items are combined to given a combined health state which can then be converted to health utilities. HUI3 score ranges from 0.36 (worst) to 1 (best).
Measured: Up to Month 24
Change from Baseline in Visual Field Readings
The progression of defects in visual fields will be assessed in both eyes using perimetry equipment.
Measured: Up to Month 24
Change from Baseline in Microperimetry Readings
MAIA microperimetry will be conducted for both eyes to assess changes other than retinal sensitivity.
Measured: Up to Month 24
Change from Baseline in Multi-Luminance Mobility Test (MLMT) Readings
The MLMT measures changes in functional vision, as assessed by the ability to navigate a course accurately and at a reasonable pace at different levels of environmental illumination.
Measured: Up to Month 24
Change from Baseline in Spectral Domain Optical Coherence Tomography (SD-OCT)
SD-OCT measurements will be performed after dilation of the participant's pupil.
Measured: Up Month 24
Change from Baseline in Fundus Autofluorescence (FAF)
Fundus Autofluorescence will be performed after dilation of the participant's pupil to assess changes in the area of viable retinal tissue.
Measured: Up to Month 24
Change from Baseline in Fundus Photography
Seven-field colour fundus photography will be used for both eyes. Fundus photography will be performed by certified technicians following pupil dilation. Stereo photos should be performed for fields 1, 2 and 3.
Measured: Up to Month 24
Change from Baseline in Adaptive-Optics Scanning Laser Ophthalmoscopy (AO-SLO)
Measurements will be performed after dilation of the participant's pupil.
Measured: Up to Month 24
Change from Baseline in Intraocular Pressure as Assessed by Goldmann Applanation Tonometry
Tonometry is used to measure eye pressure. After numbing the eye with eye drop anesthesia, the Goldmann tonometer presses against the eye. The force with which the eye pushes back is used to estimate the pressure inside the eye.
Measured: Up to Month 24
Change from Baseline in Morphology of Eye as Assessed by Slit-lamp Examination
The slit lamp exam usually forms part of a comprehensive eye exam. The participant will sit in a chair facing the slit lamp with their chin and forehead resting on a support. The doctor can use this instrument to observe the eyes in detail and determine whether or not there are any abnormalities.
Measured: Up to Month 24
Change from Baseline in Morphology of Eye as Assessed by Dilated Ophthalmoscopy
Dilated ophthalmoscopy is performed by dilating the participant's eye to see inside the fundus of the eye and other structures using an ophthalmoscope.
Measured: Up to Month 24
Change from Baseline in Morphology of Eye as Assessed by Lens Opacities Classification System (LOCS) III Lens Grading
LOCS III is a slit lamp based opacification grading method. Photographs of slit lamp cross-sections of the lens are used as references for grading nuclear opalescence (NO) and nuclear color (NC), and photographs of the lens seen by retroillumination are used as references for grading cortical (C) and posterior subcapsular (P) cataract. Opacification severity is graded on a decimal scale, scores can range from 0.1 to 6.9 for NO and NC and from 0.1 to 5.9 for C and P. For each opacification type the higher grading scores indicate greater severity.
Measured: Up to Month 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2021
- Study start13 Sep 2017
- Primary completion16 Dec 2022
- Study completion16 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for X-Linked Retinitis PigmentosaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 201 participants (actual)
Sponsor and investigators
- Lead sponsor
- NightstaRx Ltd, a Biogen Company
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Biogen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04926129
- Sponsor's protocol ID
- 274RP001
- Other IDs
- NSR-XLRP-OS1
- Acronym
- XOLARIS
- Status last verified
- Feb 2023
- First submitted
- 30 Jul 2019
- Last updated
- 10 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
von Krusenstiern L, Liu J, Liao E, Gow JA, Chen G, Ong T, Lotery AJ, Jalil A, Lam BL, MacLaren RE; XIRIUS Part 1 Study GroupXOLARIS Study Group. Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations. JAMA Ophthalmol. 2023 Mar 1;141(3):275-283. doi: 10.1001/jamaophthalmol.2022.6254.
PubMed 36757689
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Natural History of the Progression of X-Linked Retinitis Pigmentosa
- ClinicalTrials.gov ID
- NCT04926129
- Acronym / sponsor ID
- XOLARIS / 274RP001
- Conditions
- X-Linked Retinitis Pigmentosa
- Keywords
- RP GTPase regulator (RPGR), Degenerative retinal disease, XLRP, Natural history, Rare disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 201 participants (actual)
- Lead sponsor
- NightstaRx Ltd, a Biogen CompanyUniversity, hospital or other
- Study start
- 13 Sep 2017 (actual)
- Primary completion
- 16 Dec 2022 (actual)
- Study completion
- 16 Dec 2022 (actual)
- First posted
- 14 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to gain a better understanding of disease progression over time in participants with X-linked retinitis pigmentosa (XLRP).
Detailed description
This study was previously posted by NightstaRx Ltd. In October, 2020, sponsorship of the trial was transferred to Biogen.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Subgroup 1 | – | Other: Other: AssessmentsParticipant's eye with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) ≥74 letters (Equivalent to: Snellen 6/9 or 20/32; decimal 0.63; Logarithm of the minimum angle of resolution [LogMAR] 0.2) will be enrolled. |
| Subgroup 2 | – | Other: Other: AssessmentsParticipant's eye with ETDRS BCVA 34-73 letters, inclusive (Equivalent to: Snellen 6/12 - 6/60 or 20/40 - 20/200; decimal 0.5 - 0.1; LogMAR 0.3-1.0) will be enrolled. |
Who may qualify
- Ages
- 7 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- 201 participants with X-linked Retinitis Pigmentosa (XLRP).
Key inclusion criteria (7 listed)
- Have documentation of a pathogenic mutation in the retinitis pigmentosa GTPase regulator (RPGR) gene.
- Are willing and able to undergo ophthalmic examinations, as required by protocol, for up to 24 months
- Have an ETDRS BCVA in at least 1 eye of ≥34 letters (Equivalent to Snellen ≥ 6/60 or 20/200; decimal 0.1; LogMAR 1.0).
- Mean retinal sensitivity in the eligible eye as assessed by microperimetry:
- If female, have symptomatic disease with impairment of visual function.
Key exclusion criteria (4 listed)
- Have a history of amblyopia in the eligible eye.
- Have any other significant ocular or non-ocular disease/disorder which, in the opinion of the investigator, may put the participant at risk because of participation in the study, may influence the results of the study, may influence the participant's ability to perform study diagnostic tests, or impact the participant's ability to participate in the study. This includes clinically significant cataracts.
- Have participated in another research study involving an investigational medicinal product in the past 12 weeks or received a gene/cell-based therapy at any time previously (including but not limited to Intelligent Implant System implantation, ciliary neurotrophic factor therapy, nerve growth factor therapy).
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Other: AssessmentsAlso: BIIB112Administered as specified in the treatment arm. | Other | Subgroup 1, Subgroup 2 |
Primary outcome
Change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA)
Time frame: Up to Month 24
BCVA will be assessed for both eyes using the ETDRS visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant.
Change from Baseline in Retinal Sensitivity Assessed with Microperimetry
Time frame: Up to Month 24
Macular analyser integrity assessment (MAIA) microperimetry will be conducted for both eyes to assess changes in retinal sensitivity within the macula.
17 secondary outcomes
Change from Baseline in Contrast Sensitivity
Time frame: Up to Month 24
Change from Baseline in Low Luminance Visual Acuity (LLVA)
Time frame: Up to Month 24
Change from Baseline in 25-item Visual Function Questionnaire (VFQ-25) Score
Time frame: Up to Month 24
Change from Baseline in Retinitis Pigmentosa (RP)-Specific Patient-Reported Outcome (PRO) Questionnaire
Time frame: Up to Month 24
Change from Baseline in EuroQol-5 Dimension 5-level (EQ-5D-5L)
Time frame: Up to Month 24
Change from Baseline in Health Utilities Index Mark 3 (HUI3)
Time frame: Up to Month 24
Change from Baseline in Visual Field Readings
Time frame: Up to Month 24
Change from Baseline in Microperimetry Readings
Time frame: Up to Month 24
Change from Baseline in Multi-Luminance Mobility Test (MLMT) Readings
Time frame: Up to Month 24
Change from Baseline in Spectral Domain Optical Coherence Tomography (SD-OCT)
Time frame: Up Month 24
Change from Baseline in Fundus Autofluorescence (FAF)
Time frame: Up to Month 24
Change from Baseline in Fundus Photography
Time frame: Up to Month 24
Change from Baseline in Adaptive-Optics Scanning Laser Ophthalmoscopy (AO-SLO)
Time frame: Up to Month 24
Change from Baseline in Intraocular Pressure as Assessed by Goldmann Applanation Tonometry
Time frame: Up to Month 24
Change from Baseline in Morphology of Eye as Assessed by Slit-lamp Examination
Time frame: Up to Month 24
Change from Baseline in Morphology of Eye as Assessed by Dilated Ophthalmoscopy
Time frame: Up to Month 24
Change from Baseline in Morphology of Eye as Assessed by Lens Opacities Classification System (LOCS) III Lens Grading
Time frame: Up to Month 24
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2023.
- Derived from this study: PubMed 36757689von Krusenstiern L, Liu J, Liao E, Gow JA, Chen G, Ong T, Lotery AJ, Jalil A, Lam BL, MacLaren RE; XIRIUS Part 1 Study GroupXOLARIS Study Group. Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations. JAMA Ophthalmol. 2023 Mar 1;141(3):275-283. doi: 10.1001/jamaophthalmol.2022.6254.
- Individual participant dataSharing planned: No
Related trials for X-Linked Retinitis Pigmentosa
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruitingPhase 2
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
X-Linked Retinitis Pigmentosa
Active, not recruitingPhase 3
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
Retinitis Pigmentosa
Active, not recruitingPhase 3
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
X-Linked Retinitis Pigmentosa
RecruitingObservational study
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders
AMPD3, OMIM*102772, AMP Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Biogen
22 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of X-Linked Retinitis Pigmentosa, run by NightstaRx Ltd, a Biogen Company at 22 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 22 sites in United States, United Kingdom, Canada, Germany, Netherlands and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) (time frame: Up to Month 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04926129, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2023.